Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Toxins (Basel) ; 12(10)2020 09 24.
Article in English | MEDLINE | ID: mdl-32987941

ABSTRACT

Canine and human osteosarcomas (OSA) share similarities. Novel therapies are necessary for these tumours. The Bacillus anthracis toxin was reengineered to target and kill cells with high expressions of matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Since canine OSA express MMPs and uPA, we assessed whether the reengineered toxin could show efficacy against these tumours. Two OSA cell lines (canine D17 and human MG63) and a non-neoplastic canine osteoblastic cell line (COBS) were used. Cells were treated with different concentrations of the reengineered anthrax toxin and cell viability was quantified using MTT assay. The cell cycle, apoptosis, and necrosis were analysed by flow cytometry. The wound-healing assay was performed to quantify the migration capacity of treated cells. D17 and MG63 cells had significantly decreased viability after 24 h of treatment. Cell cycle analysis revealed that OSA cells underwent apoptosis when treated with the toxin, whereas COBS cells arrested in the G1 phase. The wound-healing assay showed that D17 and MG63 cells had a significantly reduced migration capacity after treatment. These results point for the first time towards the in vitro inhibitory effects of the reengineered anthrax toxin on OSA cells; this reengineered toxin could be further tested as a new therapy for OSA.


Subject(s)
Antigens, Bacterial/pharmacology , Antineoplastic Agents/pharmacology , Bacterial Toxins/pharmacology , Bone Neoplasms/drug therapy , Osteosarcoma/drug therapy , Adolescent , Animals , Antigens, Bacterial/genetics , Apoptosis/drug effects , Bacterial Toxins/genetics , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Cell Line, Tumor , Cell Movement/drug effects , Dogs , Dose-Response Relationship, Drug , Female , G1 Phase Cell Cycle Checkpoints/drug effects , Humans , Inhibitory Concentration 50 , Male , Matrix Metalloproteinases/metabolism , Membrane Proteins/metabolism , Neoplasm Invasiveness , Osteosarcoma/metabolism , Osteosarcoma/pathology , Protein Engineering
2.
Toxins (Basel) ; 12(3)2020 03 02.
Article in English | MEDLINE | ID: mdl-32121654

ABSTRACT

Canine oral mucosal melanomas (OMM) are the most common oral malignancy in dogs and few treatments are available. Thus, new treatment modalities are needed for this disease. Bacillus anthracis (anthrax) toxin has been reengineered to target tumor cells that express urokinase plasminogen activator (uPA) and metalloproteinases (MMP-2), and has shown antineoplastic effects both, in vitro and in vivo. This study aimed to evaluate the effects of a reengineered anthrax toxin on canine OMM. Five dogs bearing OMM without lung metastasis were included in the clinical study. Tumor tissue was analyzed by immunohistochemistry for expression of uPA, uPA receptor, MMP-2, MT1-MMP and TIMP-2. Animals received either three or six intratumoral injections of the reengineered anthrax toxin prior to surgical tumor excision. OMM samples from the five dogs were positive for all antibodies. After intratumoral treatment, all dogs showed stable disease according to the canine Response Evaluation Criteria in Solid Tumors (cRECIST), and tumors had decreased bleeding. Histopathology has shown necrosis of tumor cells and blood vessel walls after treatment. No significant systemic side effects were noted. In conclusion, the reengineered anthrax toxin exerted inhibitory effects when administered intratumorally, and systemic administration of this toxin is a promising therapy for canine OMM.


Subject(s)
Antigens, Bacterial/therapeutic use , Antineoplastic Agents/therapeutic use , Bacterial Toxins/therapeutic use , Dog Diseases/drug therapy , Melanoma/drug therapy , Mouth Neoplasms/drug therapy , Animals , Antigens, Bacterial/genetics , Antigens, Bacterial/pharmacology , Antineoplastic Agents/pharmacology , Bacterial Toxins/genetics , Bacterial Toxins/pharmacology , Dog Diseases/metabolism , Dog Diseases/pathology , Dogs , Female , Male , Matrix Metalloproteinase 2/metabolism , Melanoma/metabolism , Melanoma/pathology , Melanoma/veterinary , Mouth Mucosa/drug effects , Mouth Mucosa/metabolism , Mouth Mucosa/pathology , Mouth Neoplasms/metabolism , Mouth Neoplasms/pathology , Mouth Neoplasms/veterinary , Protein Engineering , Receptors, Urokinase Plasminogen Activator/metabolism , Tissue Inhibitor of Metalloproteinase-2/metabolism , Urokinase-Type Plasminogen Activator/metabolism
3.
Cell Rep ; 21(13): 3662-3671, 2017 12 26.
Article in English | MEDLINE | ID: mdl-29281816

ABSTRACT

Physiologic turnover of interstitial collagen is mediated by a sequential pathway in which collagen is fragmented by pericellular collagenases, endocytosed by collagen receptors, and routed to lysosomes for degradation by cathepsins. Here, we use intravital microscopy to investigate if malignant tumors, which are characterized by high rates of extracellular matrix turnover, utilize a similar collagen degradation pathway. Tumors of epithelial, mesenchymal, or neural crest origin all display vigorous endocytic collagen degradation. The cells engaged in this process are identified as tumor-associated macrophage (TAM)-like cells that degrade collagen in a mannose receptor-dependent manner. Accordingly, mannose-receptor-deficient mice display increased intratumoral collagen. Whole-transcriptome profiling uncovers a distinct extracellular matrix-catabolic signature of these collagen-degrading TAMs. Lineage-ablation studies reveal that collagen-degrading TAMs originate from circulating CCR2+ monocytes. This study identifies a function of TAMs in altering the tumor microenvironment through endocytic collagen turnover and establishes macrophages as centrally engaged in tumor-associated collagen degradation.


Subject(s)
Cell Movement , Collagen/metabolism , Endocytosis , Inflammation/pathology , Macrophages/pathology , Monocytes/pathology , Neoplasms/pathology , Proteolysis , Animals , Cell Polarity , Extracellular Matrix/metabolism , Lectins, C-Type , Macrophages/metabolism , Mannose Receptor , Mannose-Binding Lectins , Mice, Inbred C57BL , Neoplasms/genetics , Rats , Receptors, CCR2/metabolism , Receptors, Cell Surface , Transcriptome/genetics
4.
Oncogene ; 22(25): 3964-76, 2003 Jun 19.
Article in English | MEDLINE | ID: mdl-12813470

ABSTRACT

Keratinocytes undergo a dramatic phenotypic conversion during reepithelialization of skin wounds to become hyperproliferative, migratory, and invasive. This transient healing response phenotypically resembles malignant transformation of keratinocytes during squamous cell carcinoma progression. Here we present the first analysis of global changes in keratinocyte gene expression during skin wound healing in vivo, and compare these changes to changes in gene expression during malignant conversion of keratinized epithelium. Laser capture microdissection was used to isolate RNA from wound keratinocytes from incisional mouse skin wounds and adjacent normal skin keratinocytes. Changes in gene expression were determined by comparative cDNA array analyses, and the approach was validated by in situ hybridization. The analyses identified 48 candidate genes not previously associated with wound reepithelialization. Furthermore, the analyses revealed that the phenotypic resemblance of wound keratinocytes to squamous cell carcinoma is mimicked at the level of gene expression, but notable differences between the two tissue-remodeling processes were also observed. The combination of laser capture microdissection and cDNA array analysis provides a powerful new tool to unravel the complex changes in gene expression that underlie physiological and pathological remodeling of keratinized epithelium.


Subject(s)
Carcinoma, Squamous Cell/genetics , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Keratinocytes/metabolism , Skin Neoplasms/genetics , Skin/injuries , Wound Healing/genetics , Animals , Carcinoma, Squamous Cell/pathology , Cell Separation/instrumentation , Cell Separation/methods , Cell Transformation, Neoplastic/genetics , Epidermis/injuries , Gene Expression Profiling/methods , In Situ Hybridization , Lasers , Mice , Mice, Inbred C57BL , Oligonucleotide Array Sequence Analysis , Phenotype , RNA, Messenger/biosynthesis , RNA, Neoplasm/genetics , Reproducibility of Results , Skin/pathology , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...